Zivo Bioscience, Inc. Announces Closing of Underwriters’ Partial Exercise of Over-Allotment Option in Connection with its P...
July 02 2021 - 8:00AM
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the
“Company”), a biotech/agtech R&D company engaged in the
development and commercialization of therapeutic, medicinal and
nutritional product candidates originally derived from proprietary
algal cultures, today announced the closing of the sale of an
additional 150,000 shares of common stock, at a price to the public
of $4.99 per share less underwriting discounts and commissions,
pursuant to the partial exercise of the underwriters’
over-allotment option in connection with its previously announced
public offering that closed on June 2, 2021. ZIVO received
gross proceeds of approximately $748,500, before deducting
underwriting discounts and commissions and other estimated offering
expenses.
Maxim Group LLC acted as lead book running
manager, and Joseph Gunnar & Co., LLC acted as co-book running
manager for the offering.
The offering was conducted pursuant to the
Company's registration statement on Form S-1 (File No. 333-251221),
as amended, previously filed with and subsequently declared
effective by the Securities and Exchange Commission (“SEC”), and
the Company’s registration statement on Form S-1MEF (File No.
333-256580) filed with the SEC, which became effective upon its
filing with the SEC. A final prospectus relating to the offering
was filed with the SEC on June 1, 2021 and is available on the
SEC’s website at http://www.sec.gov. Electronic copies of the final
prospectus relating to this offering may be obtained from Maxim
Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at
(212) 895-3745.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Zivo Bioscience, Inc.
Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a
Michigan-based biotech/agtech company engaged in the investigation
of the health and nutritional benefits of bioactive compounds
derived from its proprietary algal cultures, and the development of
natural bioactive compounds for use as dietary supplements and food
ingredients, as well as biologically derived and synthetic
candidates for medicinal and pharmaceutical applications in humans
and animals, specifically focused on the general benefits of
autoimmune and inflammatory response modulation. Visit
zivobioscience.com to learn more.
Forward Looking Statements
Except for any historical information, the
matters discussed in this press release contain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Although ZIVO believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our strategic partnerships may not facilitate
the commercialization or market acceptance of our products; risks
that our products may not be ready for commercialization in a
timely manner or at all; risks that our products will not perform
as expected based on results of our pre-clinical and clinical
trials; our ability to raise additional funds; uncertainties
inherent in the development process of our products; changes in
regulatory requirements or decisions of regulatory authorities; the
size and growth potential of the markets for our products; the
results of clinical trials, our ability to protect our intellectual
property rights and other risks, uncertainties and assumptions,
including those described under the heading “Risk Factors” in our
filings with the Securities and Exchange Commission. These
forward–looking statements speak only as of the date of this press
release and ZIVO undertakes no obligation to revise or update any
forward–looking statements for any reason, even if new information
becomes available in the future.
Contact:
Investor RelationsCORE
IR516-222-2560Investor@zivobioscience.com
MediaCORE IRJules
Abraham917-885-7378julesa@coreir.com
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Sep 2023 to Sep 2024